LINZESS profits fund a GLP-2 SBS bet; apraglutide Phase 3 readout decides whether Ironwood is a royalty story or a pipeline company

Ironwood is a commercial-stage pharmaceutical company generating profits from an approved gastrointestinal treatment, LINZESS, while betting its future on apraglutide, a not-yet-approved experimental therapy for short bowel syndrome that requires patients to receive intravenous nutrition support.

Ironwood generates over $300M in annual adjusted EBITDA from LINZESS, a linaclotide franchise now expanded into pediatric GI, giving it a self-funded runway into apraglutide's Phase 3 STARS-2 trial for short bowel syndrome, a condition where patients depend on intravenous nutrition. The thesis resolves on whether STARS-2 demonstrates a statistically significant reduction in parenteral support volume, replicating the earlier Phase 3 signal in a confirmatory global randomized trial. The principal risk is that prior GLP-2 class data from a single pivotal study did not generalize across geographies, raising questions about whether STARS-2's broader enrollment will dilute the treatment effect.